NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Clinical trials for NON-ALCOHOLIC STEATOHEPATITIS (NASH) explained in plain language.
Never miss a new study
Get alerted when new NON-ALCOHOLIC STEATOHEPATITIS (NASH) trials appear
Sign up with your email to follow new studies for NON-ALCOHOLIC STEATOHEPATITIS (NASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise against fatty liver disease in Mid-Stage trial
Disease control CompletedThis study tested an experimental drug called HSK31679 in 186 Chinese adults with non-alcoholic steatohepatitis (NASH), a serious liver condition. Participants took either 80 mg, 160 mg, or a placebo daily for 52 weeks. The goal was to see if the drug could improve liver damage a…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New shot shows promise against fatty liver disease
Disease control CompletedThis study tested a weekly injection called pemvidutide in 212 adults with NASH, a serious liver condition linked to fat buildup. The goal was to see if the drug could reduce liver fat and scarring without worsening the disease. Participants received either the drug or a placebo …
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Altimmune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a weekly shot tackle fatty liver and obesity?
Disease control CompletedThis study tests a medicine called survodutide in adults with overweight or obesity and a liver condition called NASH. Participants receive weekly injections of survodutide or a placebo for about a year, along with diet and exercise advice. The goal is to see if the drug reduces …
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug shows promise for fatty liver in small trial
Disease control CompletedThis study tested a drug called TRO19622 in 22 adults with NASH, a type of fatty liver disease. Participants took the drug or a placebo for one month to see if it improved liver enzyme levels and was safe. The goal was to gather early information on whether the drug might help co…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Blood tests could spot hidden liver risk in diabetics
Knowledge-focused CompletedThis completed study observed 40 people with type 2 diabetes to find blood markers that could identify those at risk for a serious liver condition called NASH. Researchers measured liver stiffness and calculated scores like FIB-4 and ELF to see which patients might have liver sca…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Sponsor: Faculty Hospital Kralovske Vinohrady • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
First human test of AZD4076 for fatty liver begins
Knowledge-focused CompletedThis study tested a new drug called AZD4076 in 40 healthy men to see if it is safe and how the body processes it. The drug is being developed for non-alcoholic steatohepatitis (NASH), a serious liver condition. This is an early, first-in-human trial, so it focused only on safety …
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC